Press Releases
Samsung Biologics to attend DCAT Week, expand U.S. presence with New Jersey site
Samsung Biologics is participating in DCAT Week 2023 from March 20 to 23. Kevin Sharp, VP and Head of Samsung Biologics America Sales, will talk about the company’s manufacturing capacity expansion plans in a speaking session during the Member Company Announcement Forum at the event.
Already boasting 604,000 liters of biomanufacturing capacity upon the completion of its Plant 4 by midyear, Samsung Biologics is expected to maintain its capacity leadership with the addition of Plant 5 which is planned in its second Bio Campus.
The company is also expanding its U.S. presence through opening a new regional office in Ridgefield Park, New Jersey next week as part of the company’s efforts to enable streamlined communication and to work in closer proximity to its clients based in the U.S. and Europe.
Samsung Biologics is participating in DCAT Week 2023 from March 20 to 23. Kevin Sharp, VP and Head of Samsung Biologics America Sales, will talk about the company’s manufacturing capacity expansion plans in a speaking session during the Member Company Announcement Forum at the event.
Already boasting 604,000 liters of biomanufacturing capacity upon the completion of its Plant 4 by midyear, Samsung Biologics is expected to maintain its capacity leadership with the addition of Plant 5 which is planned in its second Bio Campus.
The company is also expanding its U.S. presence through opening a new regional office in Ridgefield Park, New Jersey next week as part of the company’s efforts to enable streamlined communication and to work in closer proximity to its clients based in the U.S. and Europe.